In this issue, we cover healthcare market trends and challenges, M&A trends, and regulatory developments in the Asia-Pacific region.
PwC's Global Health Industries network is pleased to present you with its 13th issue of the Asia-Pacific Health Industries Newsletter.
PwC’s 2015 State of the Internal Audit Profession Study reflects the views of more than 1300 chief audit executives, senior management and board members.
In this edition we highlight recent developments in Asia and Australia including changes in China's compliance and pricing environment, pharmaceutical deals in South Korea and India, digital health, Big Data, and tax developments in Australia, Hong Kong, China and Singapore.
PwC researches pharma relationship performance in large scale clinical outsourcing and lessons from R&D outsourcing in other hi-tech industries.
This PwC publications surveys pharmaceutical executives across the pharmaceutical value chain about the challenges on innovation in the sector.
This article lays out these and other key issues you may be facing, and offers guidance on how to bring your transfer pricing strategies up to date - while managing the expectations of multiple stakeholders.
This PwC publication provies news and analysis for pharmaceutical, biotechnology, medical device, diagnostic and healthcare companies.
In this report, we focus on how companies can reach 2020 in a position to benefit from more favourable conditions thereafter.
Asia-Pacific Pharma Newsletter, Issue 9, covers compliance updates in Australia, government price cuts in the region and tax issues in Australia, China, India, Taiwan and Singapore.
This PwC newsletter includes reports on the recent Indian and Singapore Budgets and the implications for multinationals and the local Pharma and Healthcare sectors.
PwC recently surveyed executives from leading global and domestic Medtech companies with India operations representing $1.3 billion in revenues in India, or roughly 40% of the $3 billion Indian market. Their responses, combined with in-depth interviews and PwC’s research and experience in the industry, provide insight on how to succeed in India.
PwC's Pharma 2020 series reports look into the future of the Pharmaceuticals and Life Sciences’ value chain, and they include an analysis of the strategies needed to compete successfully in the future.
PwC’s Diagnostics 2011 provides an overview of M&A deal activity during the past two years and the factors driving it, including the advance of personalised medicine and testing for earlier detection of diseases, such as cancer and Alzheimer’s. The report also includes an in-depth discussion about trends in companion diagnostics and business model considerations for pharmaceutical companies.
Puerto Rico issued final regulations December 29, 2010, under Act 154, which modifies Puerto Rican (PR) tax law by adopting new source-of-income rules and imposing a temporary excise tax on certain purchases by offshore companies whose gross receipts exceed $75 million. The new regulations follow the signing of Act 154 by Governor Luis G. Fortuño October 25, 2010, during a rare weekend legislative session. The law, enacted as part of a tax reform initiative, could raise an estimated $5.8 billion over the next six years.
Poland remains the largest clinical trials market in CEE/CIS, however, both patient participation and site penetration rates indicate a potential for growth. Launching a number of initiatives will accelerate the market growth and maximize the potential benefits to the economy.
How will IFRS 3 affect pharmaceutical and life sciences? For one, it may introduce more volatility into an acquirer's income statement. Here, we explain the changes and offer examples of how the issue may impact your company
Venture capital (VC) funding in the Life Sciences sector, which includes the biotechnology and medical device industries had record dollars in Q2 2010. Find out where the money went in PwC's MoneyTree report - based on Thomson Reuters data.
Supply Chain and Distribution/Manufacturing Services
US Healthcare reform has raised some significant accounting issues for the pharmaceutical and life sciences sector, including the annual fee on pharmaceutical manufacturers and the excise tax on medical device manufacturers
Life sciences industry ventures into social media despite regulatory uncertainty
This paper discusses how the industry is no longer being rewarded for incremental innovation, me-too products and selling the most pills. Companies need to add value to patients, and offer a package of products and health services that the market is willing to pay a premium for.
Few tax issues are more fact-intensive than determining the tax consequences to the payor of payments made under a settlement agreement with a governmental body when the agreement is silent as to the nature of the payments. In a legal advice memorandum, the IRS Office of Chief Counsel shed some light on the factors it thinks are important in such a situation. Whenever possible, of course, the taxpayer should seek to negotiate settlement agreement terms that would support the desired tax treatment.
The IRS issued temporary regulations on election and calculation of the alternative simplified research credit (ASC) under section 41(c)(5), which became effective generally for tax years ending after 2006. Under the ASC, the credit generally equals 12 percent of so much of the taxpayer's qualified research expenditures (QREs) for the calculation tax year as exceeds 50 percent of the average QREs for the three preceding tax years.
Pharma 2020: Virtual R&D explores how pharma companies could dramatically improve the R&D productivity. It contents that by 2020 the R&D process may be shortened by two-thirds, success rates may dramatically increase, and clinical trial costs could be cut substantially. New computer based technologies will create a greater understanding of the biology of disease and the evolution of ‘Virtual man’ to enable researchers to predict the effects of new drug candidates before they enter human beings.
R&D is becoming increasingly strategic for the pharmaceutical and biotechnology industries, constantly under pressure to innovate. In response to the “brain drain” experienced by France due to an obvious lack of R&D tax incentives and the fact that big pharmaceutical groups recently closed their French R&D facilities, the French government has undertaken a major reform of the R&D tax credit to maintain and promote R&D in France and make France an attractive country for innovation.
Pharma and Life Sciences Tax News Vol 7. No 6 - Roche Products Pty Limited v The Commissioner of Taxation: A bitter pill to swallow, but for whom?
But Pharma 2020: The Vision - Which Path Will You Take? indicates that the current pharmaceutical industry business model is both economically unsustainable and operationally incapable of acting quickly enough to produce the types of innovative treatments demanded by global markets. In order to make the most of these future growth opportunities, the industry must fundamentally change the way it operates.
Improving America's health IV: A survey of the working relationship between the life science industry and the FDA (Food and Drug Administration Modernization Act of 1997)
IFRS issues and solutions for the pharmaceutical industry